Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...

Dec 5 (Reuters) - A protective shield at the Chornobyl nuclear plant in war-torn Ukraine, built to contain radioactive material from the 1986 disaster, can no longer perform its main safety function ...

The protective shield built around the Chernobyl nuclear disaster site in Ukraine can no longer do its job to confine radioactive waste as a result of a drone strike earlier this year, according to ...

@2024 - All Right Reserved.

Birmingham-based Protective Life Corp. has announced two leadership changes for the new year. Paul Wells, currently an executive vice president and chief financial officer, will become president and ...

Boehringer Ingelheim has secured FDA approval for its PDE4 inhibitor nerandomilast (Jascayd) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. Nerandomilast ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, Sept. 11, 2025 ...

The last time I spoke about United Therapeutics (UTHR) it was with respect to a Seeking Alpha article entitled "United Therapeutics: Ability To Expand Tyvaso To Large IPF Market". With respect to this ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a pivotal phase 3 win in idiopathic pulmonary fibrosis (IPF). United’s Teton-2 ...

(RTTNews) - United Therapeutics Corp. (UTHR), Tuesday announced that its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for the treatment of idiopathic ...